Novo Nordisk announced that it will present 35 abstracts from its diabetes and obesity portfolio at the 61st European Association for the Study of Diabetes (EASD) Congress, scheduled from 15 to 19 September 2025 in Vienna, Austria. The data will include clinical and real-world evidence highlighting semaglutide’s broad health benefits, its wide range of approved indications, and its proven weight loss effect. The company will also showcase results from its obesity pipeline therapies, including CagriSema, cagrilintide, and amycretin.
Investor Event on 17 September
On 17 September, Novo Nordisk will host an R&D investor event to discuss the science and abstracts presented at the congress. Interested participants can access the session via a live webcast available on the Novo Nordisk investor website.
Leadership Statement
Martin Holst Lange, chief scientific officer and executive vice president, Research & Development, emphasized the company’s leadership in diabetes and obesity care. He noted, “With the broadest approved indications in both obesity and type 2 diabetes, semaglutide is helping people not only lose weight but also reduce cardiovascular risks such as heart attacks. We are now advancing next-generation therapies – such as combining cagrilintide with semaglutide or exploring it as a monotherapy – to better serve people living with diabetes and obesity. We are excited to present these data at EASD.”
Key Scientific Symposia
- SOUL Trial: Effects of oral semaglutide on cardiovascular outcomes in type 2 diabetes patients at high cardiovascular risk – Wednesday 17 September; 08:30 – 09:30 CEST
Highlighted Poster and Oral Presentations
Wegovy® (Once-weekly semaglutide 2.4 mg)
- Impact on food noise after initiating semaglutide (INFORM study): Short oral (45-SO), Tuesday 16 September; 12:00 – 13:00 CEST
- Cardiovascular events in overweight/obese adults – Danish real-world data: Oral (148-OR), Thursday 18 September; 11:30 – 11:45 CEST
Once-weekly Semaglutide 7.2 mg (STEP UP trial)
- Effect on obesity measures: Oral (145-OR), Thursday 18 September; 10:45 – 11:00 CEST
- Control of eating in adults with obesity: Oral (146-OR), Thursday 18 September; 11:00 – 11:15 CEST
- Impact on body composition and muscle strength: Oral (147-OR), Thursday 18 September; 11:15 – 11:20 CEST
Ozempic® (Once-weekly semaglutide 1.0 mg)
- Comparative effectiveness vs dulaglutide on cardiovascular outcomes in US Medicare beneficiaries: Late-breaking (LBA-19), Thursday 18 September; 10:45 – 11:00 CEST
Rybelsus® (Once-daily oral semaglutide)
- SOUL Trial – outcomes by baseline A1c and BMI: Oral (2-OR), Tuesday 16 September; 10:15 – 10:30 CEST
- SOUL Trial – effects on hospitalisation in high-risk patients: Oral (127-OR), Wednesday 17 September; 14:30 – 14:45 CEST
Semaglutide for MASH
- Liver-related responses in ESSENCE trial (post hoc analysis): Short oral (555-SO), Tuesday 16 September; 13:15 – 14:15 CEST
CagriSema
- REDEFINE 2 – combined semaglutide and cagrilintide in type 2 diabetes: Oral (73-OR), Wednesday 17 September; 09:45 – 10:00 CEST
- Glycaemic outcomes across weight loss categories in REDEFINE 2 (CGM subgroup): Oral (13-OP), Wednesday 17 September; 14:30 – 14:45 CEST
- REDEFINE 1 – combined therapy in overweight/obesity: Oral (190-OR), Thursday 18 September; 16:15 – 16:30 CEST
Cagrilintide
- Efficacy and safety in overweight/obesity – REDEFINE 1 data: Short oral (43-SO), Tuesday 16 September; 12:00 – 13:00 CEST
Amycretin
- Phase 1b/2a trial results of novel GLP-1/amylin agonist: Oral (63-OR), Tuesday 16 September; 15:15 – 15:30 CEST
- Pharmacokinetics, safety, and tolerability in renal impairment: Oral (15-OR), Wednesday 17 September; 15:00 – 15:15 CEST
- Effects on body weight and metabolic dysfunction in animals: Oral (188-OR), Thursday 18 September; 15:45 – 16:00 CEST
Looking Ahead
By presenting robust data across semaglutide, CagriSema, cagrilintide, and amycretin, Novo Nordisk underscores its leadership in addressing obesity and type 2 diabetes. As per the press release, the company continues to push the boundaries of innovation, aiming to improve patient outcomes through both established therapies and next-generation treatments.